Final Height in Girls with Central Idiopathic Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analog and Oxandrolone | Zendy

Alessandra Vottero | Zendy; Simona Pedori | Zendy; Marta Verna | Zendy; Blandina Pagano | Zendy; Marco Cappa | Zendy; Sandro Loche | Zendy; Sergio Bernasconi | Zendy; Lucia Ghizzoni | Zendy

Open Access

Final Height in Girls with Central Idiopathic Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analog and Oxandrolone

Author(s) -

Alessandra Vottero,

Simona Pedori,

Marta Verna,

Blandina Pagano,

Marco Cappa,

Sandro Loche,

Sergio Bernasconi,

Lucia Ghizzoni

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2005-1693

Subject(s) - oxandrolone , medicine , triptorelin , endocrinology , bone age , testosterone (patch) , growth hormone , gonadotropin , gonadotropin releasing hormone , hormone , luteinizing hormone

GnRH analogs (GnRHa) are considered the treatment of choice for central precocious puberty (CPP). During GnRHa administration, the suppression of the pituitary-gonadal axis results in decreased rates of linear growth and skeletal maturation and in improved adult height. However, in some patients, the growth deceleration is so marked that the expected improvement in predicted adult height is not achieved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research